Synklino completes Series A raise of EUR 29.8 million to advance clinical trials of its drug candidate for the treatment of Cytomegalovirus (CMV)
SYN002, an emerging biotech company developing breakthrough drugs for the treatment of chronic viral infections, has completed a Series A fundraise of EUR 29.8 million (DKK 222 million / USD 31.8 million) accelerating its development plans towards significant clinical milestones.
Synklino, which develops an innovative and groundbreaking drug for the treatment of cytomegalovirus (CMV) infections in transplant recipients, announces today that the company has completed a financing round of DKK 106 million/Eur 14 million corresponding to three times the original target.
Synklino ApS, a biotech company developing a first-in-class breakthrough therapy to eliminate cytomegalovirus (CMV) infections in the transplant setting, today announces the appointment of Thomas Feldthus, Lene Gerlach and Magnus Persson to its Board of Directors.
Synklino ApS, an emerging biotech company developing first-in-class breakthrough treatment to eliminate cytomegalovirus (CMV) infections in the transplant setting, today announces the appointment of Tolga Hassan as Chief Finance Officer (CFO) and Dr. Josefin-Beate (Josi) Holz as Chief Medical Officer (CMO).
Dr. Atul Humar is Director at the University of Toronto Transplant Institute, which is the largest multi-organ Transplantation Centre in North America. After two years of clinical collaboration with Synklino, he has accepted the role on the SAB.
Synklino ApS, an emerging biotech company developing first-in-class breakthrough treatment to eliminate cytomegalovirus (CMV) infections in the transplant setting, today announces the successful closing of a seed financing led by Eir Ventures and Vaekstfonden.
Synklino has set its sight on billion-dollar transplant market
We are proud to announce that the Novo Nordisk Foundation BioInnovation Institute (BII) has decided to invest DKK 10m ($1.5m) in Synklino. As a part of BII’s Creation House Programme we will have an ideal opportunity to accelerate our technical and commercial validation, to strengthen the company’s core competences, and attract additional funding that can bring our drug candidate further in pre-clinical development
John Haurum is to help Synklino develop a treatment against cytomegalovirus (CMV) infection in patients undergoing transplantation. The virus infection is quite common and often relatively harmless, but it can be more severe for transplantation patients receiving treatment with immunosuppressant drugs.
Synklino is founded by Professor in Pharmacology at the University of Copenhagen, Mette M. Rosenkilde, Ph.d. in Protein Crystallography, Mads G. Jeppesen, and life science entrepreneur Thomas N. Kledal, PhD and MBA, who is the company CEO and former head of Virology DTU, Veterinary Institute, Technical University of Denmark.